In the latest report from the Evernorth Research Institute, learn how biosimilars expand patient choice, lower specialty medication costs, and deliver meaningful savings to employers and patients.
Uncovering news and insights
We’re constantly working to unlock new ideas that can drive progress. Here you’ll find research, data analysis, and expert perspectives to help you create better outcomes for your people.
Close search filters
Changing filters will change the listed Success Criteria and Techniques
Search results (282)
Article
How to have a data-driven discussion on gene and cellular therapies
October 28, 2021
As the number of approved gene and cellular therapies grows, you can start preparing your organization now by taking the right next steps.
Article
Game changer: Three things to know about interchangeable biosimilars
October 15, 2021
The first interchangeable biosimilar is now available. Here’s what plans need to know about these products, which – like generics – can be substituted at the pharmacy.
Article
Copay Assistance Strategy Reduces Financial Burdens for Plans And Patients
October 07, 2021
Innovative solution provides $0 member cost for costly specialty drugs while reducing plans’ costs
Article
Moving beyond the rebate debate to meaningfully and effectively lower prescription drug costs
September 14, 2021
Drug prices, not rebates, are the root of the problem
Article
Antibiotic Resistance: A Threat to All Of Us
August 30, 2021
When germs no longer respond to antibiotics, the cost to our health and budgets is enormous
Article
Affordability, Cost Predictability Can Help Patients With Diabetes and Cardiovascular Disease Thrive
August 25, 2021
Budget-friendly copays encourage adherence, especially with expensive disease states.
